UNC School of Medicine Trial Explores CAR T-Cell Therapy for Lupus
A clinical trial at the University of North Carolina School of Medicine is exploring the use of CAR T-cell therapy, a treatment previously used for cancer, as a new approach to treat lupus patients. The therapy involves genetically reprogramming a…
Terre Haute, IN, October 15, 2026 —
A clinical trial at the University of North Carolina School of Medicine is exploring whether CAR T-cell therapy could offer a new approach to treating lupus. The treatment has previously been used for cancer, and in this trial it involves genetically reprogramming a patient’s T-cells to target autoreactive B cells.
Autoreactive B cells play a role in autoimmune diseases such as lupus, according to the information provided about the trial. The approach is intended to target those cells using the reprogrammed T-cells. The summary describes results for patients as promising, but does not provide measurements or details that would show the scale or nature of those results.
Information about the number of patients involved, the trial’s phase, its start date or duration, and the specific outcomes observed was not provided. The summary also does not identify the researchers leading the work or describe how the treatment is administered. Without those details, the findings cannot be assessed further from the available information.
The trial is investigating a potential use of a therapy previously used for cancer in people with lupus. The information provided does not establish whether the approach has been approved as a lupus treatment or whether it is available outside the trial. It also does not specify what further steps may follow the reported results.
Story summarized from the original created by Tisha Powell on www.wthitv.com, see more information here.
Media gallery
